Daily injections of DTPA, begun 3 days after administration of Pu239 to mice, were continued for various intervals of from 1-12 days. Significant increase in survival followed 8 or 12 days of DTPA. Treatment given for 12 days removed 43.2 per cent of the skeletal plutonium and reduced the fraction of mice with bone tumors by 42.5 per cent at the time the last control animal had died. Two days of therapy had less effect on removal and tumor incidence. Bone tumor rate increased with time after plutonium injection. It was lowered significantly by treatment given for 12 days.
Monomeric and polymeric plutonium solutions were injected intravenously into rats. Polymeric plutonium disappeared from the plasma faster than the monomeric form (e.g., at l$hr, the plasma contained 23per cent of the injected polymeric plutonium versus 34percent of the monomeric form). DTPA, given intraperitoneally 30 min after plutonium,. reduced the plasma content of both forms to about 12 per cent of injected plutonium at 14 hr, although the removal of the monomeric form was faster. The ultrafiltrate from plasma of untreated rats after injection of either form contained less than 0.01 per cent of injected plutonium over the first 24 hr. After DTPA treatment, more of the monomeric than of the polymeric plutonium was ultrafilterable (e.g., 36 per cent versus 8 per cent at 3 hr).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.